Cartesian Therapeutics Inc. Common Stock (RNAC)

About RNAC

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasth…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

75

Website

www.cartesiantherapeutics.com

Fundamentals

1-day range

$9.33$10.87

Market cap

$257.38M

P/E (trailing)

—

P/E (forward)

-2.75

EPS (trailing)

$-5.78

Dividend yield

—

Beta

0.56

Avg. volume

267.7K

Forecasts

7 analyst ratings

Cartesian Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RNAC

  Cartesian Therapeutics Inc. Common Stock

  $9.6

  ▼ 3.71%
  Market cap $257.38MP/E —
  $5.6$11.8
• AKBA

  Akebia Therapeutics Inc. Common Stock

  $0.879

  ▼ 6.49%
  Market cap $256.03MP/E —
  $0.814$3.22
• MGNX

  MacroGenics Inc. Common Stock

  $4.13

  ▲ 1.23%
  Market cap $254.89MP/E —
  $1.29$5.08
• WHWK

  Whitehawk Therapeutics Inc. Common Stock

  $4.65

  ▼ 4.52%
  Market cap $252.78MP/E —
  $1.76$5.5
• VRXA

  Veraxa Biotech AG Ordinary Shares

  $1.36

  ▼ 5.56%
  Market cap $263.02MP/E —
  $1.32$27.36
• ELDN

  Eledon Pharmaceuticals Inc. Common Stock

  $3.19

  ▼ 3.92%
  Market cap $267.07MP/E —
  $1.35$4.6
• SLGL

  Sol-Gel Technologies Ltd. Ordinary Shares

  $69.41

  ▼ 4.35%
  Market cap $244.18MP/E —
  $21$97.97

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
  Benzinga · 8/18/2026
• Adicet Bio: A Cheap Gamma Delta T-Cell Play
  SeekingAlpha · 8/14/2026
• Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
  Benzinga · 8/6/2026

• Seven One Eight Three Four Irrevocable Trust · April 2, 2026 · Option Exercise

  22.7K
• Seven One Eight Three Four Irrevocable Trust · April 2, 2026 · Option Exercise

  758.0K
• Kalayoglu Murat · April 2, 2026 · Option Exercise

  22.7K
• Kalayoglu Murat · April 2, 2026 · Option Exercise

  758.0K
• Singer Michael · March 13, 2026 · Gift

  6.6K

Institutional Ownership

March 31, 2026

Total shares held

7.01M

Total value held

$42.84M

Institutional holders

79